Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158 Reference Formulation, ABI-H2158 Test Formulation; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: Divalproex Sodium, Depakote®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: East Grand Forks, Minnesota

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Seizures
Interventions: Levetiracetam; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Nonhematologic Malignancies, Lymphoma
Interventions: Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B, Ketoconazole, Rifampin, Clarithromycin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Panic Disorder
Interventions: Paroxetine, Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non Small Cell Lung Cancer, NSCLC
Interventions: CoreDx Pulmonary Mini-Forceps; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions: Inhaled Technosphere Insulin; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more

Conditions: Liver Transplant Surgery
Interventions: TetraGraph on dominant hand, TetraGraph on non-dominant hand; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Renal Insufficiency
Interventions: Gefapixant; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Postoperative Pain
Interventions: EXPAREL and Local Anesthetics, Oral Opioid and Local Anesthetics; Procedure
Lead sponsor: Bellaire Facial Surgery Center; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Atlanta, Georgia • Houston, Texas • The Woodlands, Texas

Conditions: Lung Biopsy, Lung Cancer, Lung Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Invenio Imaging Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 7
States / cities: San Diego, California • Jacksonville, Florida • Grand Rapids, Michigan + 4 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Bevacizumab and Erlotinib; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Neoplasms
Interventions: GSK2636771, Enzalutamide; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Developmental & Technological Demands, Distress Reduction, Nutrition, Set Point, & C:I Ratio, Hypoglycemia management, Minimal Intervention; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 6 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lymphangioleiomyomas, Tuberous Sclerosis, Lymphangioleiomyomatosis
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Food Effect in Healthy Participants
Interventions: E7386; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obstructive Sleep Apnea, Cognitive Decline
Interventions: Positive airway pressure, Oral appliance therapy, Positional therapy; Device
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 55 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Tucson, Arizona • New York, New York • Pittsburgh, Pennsylvania

Conditions: Gastric Ultrasound, Glucagon-like Peptide 1, Point of Care Ultrasound
Interventions: Gastric Ultrasound Exam; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 99 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Jacksonville, Florida • Albany, New York + 2 more

Conditions: Depression
Interventions: PRogram In Support of Moms (PRISM), MCPAP for Moms; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Transplants and Implants
Interventions: Prednisone, rabbit antithymocyte globulin, Tacrolimus, Mycophenolate mofetil; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 19 Years to 74 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder
Interventions: LY03005, Pristiq; Drug
Lead sponsor: Luye Pharma Group Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Eatontown, New Jersey

Search by objective public record fields.

A Study to Assess the Relative Bioavailability and Food Effect of ABI-H2158 in Healthy Adults

A Study to Assess the Relative Bioavailability of Immediate Release Formulations of ABBV-903 in Healthy Adult Participants

Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

Blood Markers of Early Pancreas Cancer

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

Sugammadex and Quantitative Monitoring in "Fast-Track Anesthesia" During Liver Transplantation

The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)

Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain

A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer

Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System

Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women

A Food-Effect Study of E7386 in Healthy Participants

The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

Gastric Ultrasound Assessment for Patients Taking GLP1 Agonists

PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics

Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®